Abbott and Biotest Enter Agreement to Develop Antibody for Autoimmune Diseases

Abbott Laboratories (Abbot Park, IL, USA), a broad-based health care company and Biotest AG (Dreieich, Germany), a pharmaceutical and biotherapeutic provider, announced that they have signed a global agreement to develop and commercialize BT-061. This novel anti-CD4 antibody, which is now in Phase II clinical trials for rheumatoid arthritis (RA) and psoriasis, is also in preclinical studies for its potential use in other immune-related diseases.

BT-061, a humanized monoclonal antibody, works by activating the body’s T-regulatory cells, a subset of T-cells, which strengthen a natural function of the body that prevents excessive immune reactions. BT-061 differs from other anti-CD4 antibodies being developed since it does not cause depletion of CD4 positive T-cells that would cause weakened immune responses.

“Though the research is still early, BT-061 has the potential to become an important treatment option for patients suffering from autoimmune diseases,” said John Leonard, MD, senior vice president, global research and development, Abbott. “This novel compound will strengthen Abbott's immunology pipeline and we look forward to continuing to build on our expertise in exploring multiple mechanisms and approaches to treat inflammatory diseases.”

"Biotest is pleased to continue the development of BT-061 together with Abbott, one of the world leaders in the development and commercialization of biologic drugs for the treatment of immunological diseases," said Prof. Dr. Gregor Schulz, CEO of Biotest AG. "With its tremendous experience in the field and its global commercial strength and presence, Abbott is the perfect partner for maximizing the therapeutic and commercial potential of BT-061."

Related Links:
Abbott
Biotest